Singapore-based firm on track to commercialise cancer drug
Tessa Therapeutics teams up with California institute to run cancer-therapy trial, commercial launch expected in 2020
Singapore
SCIENTISTS are now a step closer to turning cancer patients' own immune cells (T-cells) against the tumours in their bodies - and possibly finding a cure for the dreaded disease.
A Singapore-based biotechnology firm has emerged ahead of the very crowded research field of T-cell immunotherapy, by conducting the world's first US Food and Drug Administration (FDA) Phase Three cancer T-cell therapy trial involving a number of hospitals and treatment centres across the world.
This means Tessa Therapeutics will produce the world's first commercial T-cell therapy treatment for solid tumours.
Tessa announced last week that it has set up a multi-year strategic alliance with …
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
International
UN chief warns Mideast on brink of 'full-scale regional conflict'
IMF boss says ‘all eyes’ on US amid risks to global economy
UK financial sector seeks stronger accountability of regulators
US weekly jobless claims unchanged at low levels
China's central bank signals caution over credit boost as demand weakens
Former China central bank’s deputy governor accused of taking bribes